Peter Moldt

Partner at Novo Ventures (US), Inc.

Peter Moldt

Peter Moldt

Partner at Novo Ventures (US), Inc.

Overview
Career Highlights

7TM A/S
Curalogic AS

RelSci Relationships

1463

Number of Boards

16

Birthday

1959

Age

60

Contact Data
Trying to get in touch with Peter Moldt? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Peter Moldt likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Partner at Pivotal Bioventure Partners Investment Advisor LLC

Relationship likelihood: Strong

Former Director-Irhythm at iRhythm Technologies, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Lundbeckfonden Ventures

Relationship likelihood: Strong

Founder at BioClin Therapeutics, Inc.

Relationship likelihood: Strong

Managing Director at Vivo Capital LLC

Relationship likelihood: Strong

Scientific Founder at Arch Oncology, Inc.

Relationship likelihood: Strong

Member of the Editorial Board at Expert Opinion on Therapeutic Patents Journal

Relationship likelihood: Strong

Former Chief Business Officer at NeuroSearch A/S

Relationship likelihood: Strong

Partner & Head of Growth Equity Investments at Adams Street Partners LLC

Relationship likelihood: Strong

Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Paths to Peter Moldt
Potential Connections via
Relationship Science
You
Peter Moldt
Partner at Novo Ventures (US), Inc.
Education
Doctorate Degree

Danmarks Farmaceutiske Universitet.

Graduate

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Career History
Partner
2012 - Current

Novo Ventures US invests venture capital in biotechnology and life science companies throughout the US and Europe. Their typical investments are as equity ranging from 1 to 15 million Euro. The firm may invest at any stage of development of a business idea - from seed capital over private placements to IPOs and public companies and they may invest in any part of the world.

Partner
Current

Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA.

Partner
2009 - 2012

Novo Ventures is an active manager which provides funding for early and later-stage capital requirements, and provides management support. The firm invests in both public and private companies from Northern Europe and the United States. Novo Ventures targets companies operating in the health technology and health services sector, and industries such as biotechnology and medical specialties. It looks to take minority stake positions in its investments, as well as a seat on the board.

Boards & Committees
Director
Prior - 2010

Neurokey wants to become a leading drug development company in the critical care field.The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.

Non-Executive Director
Prior

Biotica Technology Ltd. develops and manufactures pharmaceutical products. The company focuses on the discovery and development of novel therapeutics derived from polyketide through the targeted alteration of polyketide biosynthetic pathways. The firm was founded in 1996 by Peter Leadlay and Jim Staunton and is headquartered in Saffron Walden, GB.

Director
Prior

Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Mørkeberg Hinsby, Martin Rahbek Kornum, Marja Jäättela, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Investments
Details Hidden
Details Hidden
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Peter Moldt. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Peter Moldt's profile does not indicate a business or promotional relationship of any kind between RelSci and Peter Moldt.